This is the authors' abstract. We don't add key points for this paper.
This is the largest survey in the UK completed by patients who experienced an adverse outcome following the aesthetic administration of Botulinum Toxin. Our study highlights the extent of the challenges faced by patients who experience an adverse event from physical, emotional, psychological, and financial perspectives. The lack of awareness of MHRA reporting structures and the lack of regulation within the UK's cosmetic injectables sector represent a significant public health challenge.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zargaran et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: